PRESS-RELEASE filed May 28, 2026 at 16:00 ET
Outlook Therapeutics announces a $5.0M registered direct offering of 8.54M shares at $0.5855/share to its largest stockholder, GMS Ventures and Investments. The company also agrees to amend 15.49M outstanding warrants with a weighted average exercise price of $1.78 to a reduced exercise price of $0.5855, effective at closing. This dilutive capital raise comes as the company (market cap ~$71M) is commercializing LYTENAVA in Europe with an ongoing US FDA approval path. The aggressive warrant repricing creates massive potential dilution, effectively rewarding GMS with a near-$18M intrinsic-value transfer on existing warrants.